Go Back
Description
Expected Outcome
Scope
Partner Requests
Contact
Related Fundings
Add to favorites:
Share:

Development of antibodies and antibody-derived proteins for the prevention and treatment of infectious diseases with epidemic potential

This funding call aims to support research and development of antibodies and antibody-derived proteins to address infectious diseases with epidemic potential. The call focuses on advancing the understanding of prophylactic and therapeutic options for emerging and re-emerging viral infections. Proposals should address preclinical studies, GMP-quality test batch preparation, and first-in-human clinical safety studies. Targeted viruses include Arenaviridae (e.g., Lassa mammarenavirus), Hantaviridae (e.g., Hantaan virus), and others, with a focus on affordability and large-scale production for pandemic response.

Opening: 22-05-2025
Deadline(s): 18-09-2025

Data provided by Kooperationsstelle Wissenschaft

This funding opportunity represents a pre-agreed draft that has not yet been officially approved by the European Commission. The final, approved version is expected to be published in the first quarter of 2025. This draft is provided for informational purposes and may be used to preliminarily form consortia and develop project ideas, but it is offered without any guarantees or warranties.

Expected Outcome

• Improved understanding of antibody-based prophylactic and therapeutic options for epidemic-potential viruses
• Availability of experimental antibodies for prevention and treatment
• Candidate antiviral therapies for clinical deployment during epidemics and pandemics

Scope

• Development of antibodies and antibody-derived proteins targeting specific epidemic-potential viruses
• Preclinical in vitro and in vivo testing to demonstrate efficacy and safety
• Production of GMP-quality test batches within the EU/EEA
• Conducting first-in-human clinical safety studies
• Collaboration with regulatory bodies and endemic regions

Partner Requests

Explore Real Collaboration Opportunities

🔍 As a logged-in member, you now have exclusive access to all active Partner Requests for this Funding Call.
See who’s looking for collaborators, explore exciting project ideas, and discover how others are planning to make an impact.

💡 Use these insights to get inspired—or take the next step and start a request of your own (available to premium members only).

Log in or registrate here for free.

Create a Partner Request for this Funding Call!

🔒 Unlock the full power of our Partner Request Tool—connect directly with potential collaborators, send tailored requests, and boost your chances of success through strategic partnerships. This exclusive feature is only available to our premium members.

Upgrade to Premium now and start building valuable connections today! Already a premium member? Log in here to access your requests.

Ask our experts about this call

Connect with the Listing Owner!

💬 Please log in now to send a direct message to our experts and ask your questions. Not a member yet? Sign up for free and start connecting today!

Related Funding and Finance Opportunities

Unlock Exclusive Funding Opportunities!

🔑 Get instant access to tailored funding opportunities that perfectly match your needs. This powerful feature is exclusively available to our premium members—helping you save time, stay ahead of the competition, and secure the right funding faster.

Upgrade to Premium now and never miss an important opportunity again! Already a premium member? Log in here to explore your matches.

Related Innovation Offers

Discover Tailored Innovation Offers!

🚀 Gain access to technology solutions that match your specific needs and interests—carefully selected to support your innovation goals. These offers are exclusively available to our premium members, helping you identify relevant technologies faster and start the right conversations with potential partners.

Upgrade to Premium now and explore your personalized technology matches today! Already a premium member? Log in here to view your tailored offers.